Skip to main content
OpenTrials
Completed

NCT Number: NCT07103720

The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

Perioperative anaphylaxis is a potentially life-threatening drug allergic reaction that can occur during anesthetic procedures. The purpose of this research is to determine the maximal nonirritating skin testing concentrations of midazolam, ketamine and ondansetron. These drugs are FDA approved and commonly used before, during and after surgical procedures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergy Hypersensitivity Immune System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Mayo Clinic Arizona

Scottsdale, Arizona, 85268, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Not have a history of an adverse reactions to midazolam, ketamine or ondansetron
  • Ability to understand study procedures and to comply with them for the entire length of the study.
  • Contraception is not necessary, and we will include women of reproductive capability.

Exclusion criteria

  • Unstable patients.
  • History of any adverse reaction (allergy or sensitivity) to midazolam, ketamine or ondansetron.
  • Pregnant and Pediatric patients
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Treatment and study plan

skin testing

Diagnostic Test

Participants will undergo skin prick testing and intradermal test injections at 5 increasing concentrations of midazolam, ketamine and/or ondansetron during one single study visit.

Primary outcomes

  1. Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron.

    Time frame: 1 Day

    Determine the maximal nonirritating concentrations of midazolam, ketamine and ondansetron

Secondary outcomes

  1. Skin Testing Results

    Time frame: 1 Day

    Determine the frequency of false positive test results in patients who have received Midazolam, Ketamine or Ondansetron in the past.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • Arizona Biomedical Research Commission (ABRC)

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 5, 2025
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.